MarketCap
Facebook
X
Telegram
Pharming Group N.V. Income Statement 2025-2011 | PHAR
Brief overview of revenue and earnings at Pharming Group N.V.
The figures are compared over a five-year interval. According to figures from Pharming Group N.V., revenue changed from 10.8 million euros to 186 million euros over five years. Across the full period, sales moved by +1614.9%; the average annual rate was 76.5%. This pace points to rapid expansion of the business.
The five-year change in gross profit reached +2638.8%: from 6 million euros to 165 million euros. Gross profit as a share of revenue changed from 55.7% to 88.9%. A wider margin shows that the economics of the core business improved.
The five-year EBITDA result moved by +648.7%: from −13.5 million euros to 74 million euros. EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from −124.6% to 39.9%. The company improved its ability to convert sales into EBITDA.
Across the five years, the net result shifted from −10 million euros to 33 million euros. The trajectory reversed from a loss to positive earnings.
What the figures show
Most key measures improved without a pronounced weak signal. The positive side is supported by an improving EBITDA margin, net-income growth and improving gross profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Pharming Group N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
11.8 B | 5.16 B | 6.92 B | 7.67 B | 5.94 B | 868 M | - | - | - | - | - | - | - | - | - |
Shares |
689 M | 671 M | 657 M | 649 M | 642 M | 63.6 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
17.1 | 7.69 | 10.5 | 11.8 | 9.25 | 13.6 | - | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | - | - | 33 M | 36.2 M | 25 M | -80 M | -17.5 M | -9.96 M | -5.77 M | -15.1 M | -24.1 M | -17.1 M |
Revenue |
- | - | - | - | - | 186 M | 169 M | 135 M | 89.6 M | 15.9 M | 10.8 M | 21.2 M | 6.84 M | 10.6 M | 3 M |
Cost of Revenue |
- | - | - | - | - | 20.6 M | 21.4 M | 22.2 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 113 M | 77.2 M | 11.2 M | 6.03 M | 17.8 M | 5.73 M | 6.35 M | -531 K |
Operating Income |
- | - | - | - | - | 66.7 M | 60.9 M | 38 M | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | 10 K | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | 74 M | 66.1 M | 44.6 M | 25.3 M | -10.8 M | -13.5 M | 3.06 M | -11.5 M | -19.6 M | -18.6 M |
Operating Expenses |
- | - | - | - | - | 98.4 M | 86.8 M | 75 M | 55.3 M | 22.7 M | 18.9 M | 14.9 M | 12.6 M | 22.6 M | 17.9 M |
General and Administrative Expenses |
- | - | - | - | - | 11.7 M | 18.9 M | 12.2 M | 5.97 M | 4.64 M | 3.74 M | 3.32 M | 2.52 M | 3.45 M | 3.26 M |
All numbers in EUR currency
Quarterly Income Statement Pharming Group N.V.
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
689 M | 671 M | 657 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
The income statement is one of the three key financial reports of a company Pharming Group N.V. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
